Sauri Gudlavalleti joins Sai Life Sciences as COO
Mr. Gudlavalleti joins Sai Life Sciences from Dr. Reddy's Laboratories where he was heading Global R&D and Portfolio Management for small molecule API & Formulations, encompassing portfolio & strategy, development, technology transfer, CRO/ CDMO partnerships, IP, regulatory affairs and clinical affairs.
Over his 7-year tenure there, he spearheaded a multifold increase in the R&D pipeline, significantly globalized the R&D efforts with an impetus on fast-growing emerging markets and brought about a pioneering transformation in R&D through data and analytics.
More recently, he led the development, approval and launch of the company's covid portfolio, partnering with global large pharma innovators, in record time.
Before Dr. Reddy's, Mr. Gudlavalleti was at McKinsey & Co. for six years where he successfully delivered on several client engagements with focus on operational transformation spanning product development, service delivery and manufacturing operations.
Previously, he spent 9 years in the US, working on advanced technologies at MIT, GE and Qualcomm.
Mr. Gudlavalleti holds 9 US patents and has published in multiple peer-reviewed journals and conferences. ■